TY - JOUR T1 - Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV coinfection JF - JAMA Y1 - 2015 A1 - Osinusi, A. A1 - Townsend, K. A1 - Kohli, A. A1 - Nelson, A. A1 - Seamon, C. A1 - Meissner, E.G. A1 - Bon, D. A1 - Silk, R. A1 - Gross, C. A1 - Price, A. A1 - Sajadi, M. A1 - Sidharthan, S. A1 - Sims, Z. A1 - Herrmann, E. A1 - Hogan, J. A1 - Teferi, G. A1 - Talwani, R. A1 - Proschan, M. A1 - Jenkins, V. A1 - Kleiner, D.E. A1 - Wood, B.J. A1 - Subramanian, G.M. A1 - Pang, P.S. A1 - J G McHutchison A1 - Polis, M.A. A1 - Fauci, A.S. A1 - Masur, H. A1 - Kottilil, S. KW - adherence KW - Antiretroviral KW - Antiretroviral Therapy KW - Baltimore KW - California KW - Cities KW - co-infected KW - co-infection KW - coinfection KW - Counseling KW - deep sequencing KW - Disease KW - Family KW - Genotype KW - genotype 1 KW - Germany KW - HCV KW - Health KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Hiv KW - HIV RNA KW - Human KW - immunology KW - Infection KW - interferon KW - interventions KW - Laboratories KW - Maryland KW - Medicine KW - microbiology KW - Mutation KW - NS5A inhibitor KW - pathology KW - Patients KW - Plasma KW - Radiology KW - Research KW - resistance KW - Rna KW - Safety KW - sofosbuvir KW - South Carolina KW - sustained virologic response KW - SVR KW - therapy KW - treatment KW - Universities KW - virology KW - Washington VL - 313 SP - 1232-1239 IS - 12 ER -